Name | Number of supported studies | Average coverage | |
---|---|---|---|
eye | 8 studies | 38% ± 21% | |
intestine | 7 studies | 24% ± 10% | |
lung | 6 studies | 29% ± 11% | |
peripheral blood | 4 studies | 24% ± 7% | |
uterus | 4 studies | 26% ± 11% | |
pancreas | 3 studies | 42% ± 13% | |
kidney | 3 studies | 25% ± 9% | |
placenta | 3 studies | 23% ± 10% | |
bone marrow | 3 studies | 20% ± 2% | |
brain | 3 studies | 21% ± 7% | |
liver | 3 studies | 39% ± 15% | |
thymus | 3 studies | 39% ± 25% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 4103.85 | 1808 / 1809 | 100% | 30.50 | 471 / 472 |
brain | 100% | 3110.58 | 2630 / 2642 | 100% | 26.38 | 703 / 705 |
prostate | 100% | 1741.37 | 244 / 245 | 99% | 18.24 | 497 / 502 |
breast | 100% | 2092.79 | 457 / 459 | 99% | 26.37 | 1107 / 1118 |
stomach | 99% | 1354.98 | 355 / 359 | 100% | 34.41 | 285 / 286 |
ovary | 98% | 1336.67 | 177 / 180 | 100% | 44.57 | 430 / 430 |
intestine | 97% | 1356.58 | 933 / 966 | 99% | 36.09 | 524 / 527 |
uterus | 96% | 1664.88 | 163 / 170 | 100% | 30.34 | 458 / 459 |
esophagus | 94% | 1873.87 | 1352 / 1445 | 100% | 29.15 | 183 / 183 |
adrenal gland | 100% | 3394.84 | 258 / 258 | 93% | 16.00 | 213 / 230 |
pancreas | 99% | 1585.22 | 324 / 328 | 94% | 14.45 | 167 / 178 |
bladder | 90% | 2308.19 | 19 / 21 | 100% | 33.56 | 504 / 504 |
lung | 93% | 1809.95 | 537 / 578 | 97% | 22.33 | 1116 / 1155 |
liver | 98% | 1983.94 | 221 / 226 | 91% | 18.41 | 370 / 406 |
thymus | 99% | 1611.05 | 644 / 653 | 86% | 11.23 | 520 / 605 |
kidney | 100% | 1981.56 | 89 / 89 | 74% | 10.90 | 669 / 901 |
eye | 0% | 0 | 0 / 0 | 100% | 20.46 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 45.26 | 29 / 29 |
tonsil | 0% | 0 | 0 / 0 | 100% | 20.28 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 38.97 | 1 / 1 |
spleen | 100% | 1977.45 | 240 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 2093.58 | 1196 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 1384.68 | 1225 / 1335 | 0% | 0 | 0 / 0 |
heart | 86% | 1036.10 | 739 / 861 | 0% | 0 | 0 / 0 |
muscle | 80% | 880.03 | 643 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 50% | 2259.72 | 461 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0006897 | Biological process | endocytosis |
GO_0006228 | Biological process | UTP biosynthetic process |
GO_0050679 | Biological process | positive regulation of epithelial cell proliferation |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0006259 | Biological process | DNA metabolic process |
GO_0030154 | Biological process | cell differentiation |
GO_0043388 | Biological process | positive regulation of DNA binding |
GO_0006183 | Biological process | GTP biosynthetic process |
GO_0007595 | Biological process | lactation |
GO_0007399 | Biological process | nervous system development |
GO_0006241 | Biological process | CTP biosynthetic process |
GO_0032587 | Cellular component | ruffle membrane |
GO_0016020 | Cellular component | membrane |
GO_0005769 | Cellular component | early endosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004536 | Molecular function | DNA nuclease activity |
GO_0004550 | Molecular function | nucleoside diphosphate kinase activity |
GO_0043024 | Molecular function | ribosomal small subunit binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0008408 | Molecular function | 3'-5' exonuclease activity |
GO_0005525 | Molecular function | GTP binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NME1 |
Protein name | Nucleoside diphosphate kinase A (NDK A) (NDP kinase A) (EC 2.7.4.6) (Granzyme A-activated DNase) (GAAD) (Metastasis inhibition factor nm23) (NM23-H1) (Tumor metastatic process-associated protein) nucleoside-diphosphate kinase (EC 2.7.4.6) |
Synonyms | NM23 NDPKA |
Description | FUNCTION: Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. During GZMA-mediated cell death, works in concert with TREX1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair. . |
Accessions | C9K028 ENST00000456492.1 ENST00000013034.3 [P15531-2] E5RHP0 ENST00000393196.8 [P15531-1] E7ERL0 ENST00000480143.5 ENST00000511355.5 ENST00000475573.5 ENST00000336097.7 [P15531-2] P15531 |